HC Wainwright Reiterates Buy Rating for Zevra Therapeutics (NASDAQ:ZVRA)

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 191.97% from the stock’s previous close. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2026 earnings at $0.59 EPS, FY2027 earnings at $2.27 EPS and FY2028 earnings at $2.71 EPS.

Several other research firms have also weighed in on ZVRA. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Wednesday, August 14th. Maxim Group upped their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group reduced their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, September 18th. Finally, Roth Mkm boosted their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $6.85 on Monday. The stock has a market cap of $286.69 million, a price-to-earnings ratio of -5.07 and a beta of 1.94. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. Zevra Therapeutics has a 12 month low of $3.89 and a 12 month high of $8.95. The stock’s 50 day moving average price is $7.17 and its 200 day moving average price is $5.76.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The firm had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. During the same period in the prior year, the firm posted ($0.15) EPS. Equities research analysts anticipate that Zevra Therapeutics will post -1.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director John B. Bode purchased 10,000 shares of the stock in a transaction that occurred on Friday, July 12th. The stock was acquired at an average price of $5.87 per share, with a total value of $58,700.00. Following the purchase, the director now owns 30,000 shares in the company, valued at approximately $176,100. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have bought 22,000 shares of company stock worth $140,340 over the last 90 days. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Zevra Therapeutics

Large investors have recently made changes to their positions in the stock. Armistice Capital LLC acquired a new stake in Zevra Therapeutics in the 4th quarter worth approximately $1,755,000. Jacobs Levy Equity Management Inc. lifted its stake in shares of Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after buying an additional 17,557 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Zevra Therapeutics during the 4th quarter worth $177,000. Focus Financial Network Inc. ADV acquired a new position in Zevra Therapeutics in the 4th quarter valued at $141,000. Finally, Price T Rowe Associates Inc. MD bought a new position in Zevra Therapeutics in the 1st quarter worth $64,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.